Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity.

Linazasoro G.

Trends Pharmacol Sci. 2005 Aug;26(8):391-7. Review.

PMID:
16009432
2.

[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].

Damier P, Tremblay L, Féger J, Hirsch EC.

Rev Neurol (Paris). 2000 Mar;156(3):224-35. Review. French.

PMID:
10740093
3.

Levodopa in the early treatment of Parkinson's disease.

Murata M.

Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S17-20. doi: 10.1016/S1353-8020(09)70006-9. Review.

PMID:
19131036
4.

Risk factors in development of motor complications in Chinese patients with idiopathic Parkinson's disease.

Kum WF, Gao J, Durairajan SS, Man SC, Xie LX, Lu JH, Fong WL, Li M.

J Clin Neurosci. 2009 Aug;16(8):1034-7. doi: 10.1016/j.jocn.2008.10.015. Epub 2009 May 9.

PMID:
19428256
5.

Treatment of Parkinson's disease: levodopa as the first choice.

Katzenschlager R, Lees AJ.

J Neurol. 2002 Sep;249 Suppl 2:II19-24. Review.

PMID:
12375059
6.

[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].

Maurel F, Lilliu H, Le Pen C.

Rev Neurol (Paris). 2001 May;157(5):507-14. French.

PMID:
11438770
7.

Opioids and motor complications in Parkinson's disease.

Samadi P, Bédard PJ, Rouillard C.

Trends Pharmacol Sci. 2006 Oct;27(10):512-7. Epub 2006 Sep 5.

PMID:
16908075
8.

Genetic polymorphism of the angiotensin converting enzyme and L-dopa-induced adverse effects in Parkinson's disease.

Lin JJ, Yueh KC, Lin SZ, Harn HJ, Liu JT.

J Neurol Sci. 2007 Jan 31;252(2):130-4. Epub 2006 Dec 28.

PMID:
17196621
9.

[Physiopathology of the dyskinesias induced by L-dopa].

Grandas F, López-Ariztegui N.

Rev Neurol. 1997 Aug;25 Suppl 2:S151-6. Review. Spanish.

PMID:
9280682
10.

Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease.

Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y.

Mov Disord. 2001 Jul;16(4):708-13.

PMID:
11481696
11.

[Dyskinesia caused by L-DOPA].

Derkinderen P, Vidailhet M.

Rev Neurol (Paris). 2002 Dec;158 Spec no 1:S92-101. Review. French.

PMID:
12690668
12.

Pathological synaptic plasticity in the striatum: implications for Parkinson's disease.

Picconi B, Pisani A, Barone I, Bonsi P, Centonze D, Bernardi G, Calabresi P.

Neurotoxicology. 2005 Oct;26(5):779-83. Epub 2005 May 31. Review.

PMID:
15927256
13.

Dyskinesias predict the onset of motor response fluctuations in patients with Parkinson's disease on L-dopa monotherapy.

Mazzella L, Yahr MD, Marinelli L, Huang N, Moshier E, Di Rocco A.

Parkinsonism Relat Disord. 2005 May;11(3):151-5.

PMID:
15823479
14.

Synaptic dysfunction in Parkinson's disease.

Bagetta V, Ghiglieri V, Sgobio C, Calabresi P, Picconi B.

Biochem Soc Trans. 2010 Apr;38(2):493-7. doi: 10.1042/BST0380493. Review.

PMID:
20298209
15.

Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients.

Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C.

Acta Neurol Scand. 1998 May;97(5):295-9.

PMID:
9613557
16.

Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias.

Morgante F, Espay AJ, Gunraj C, Lang AE, Chen R.

Brain. 2006 Apr;129(Pt 4):1059-69. Epub 2006 Feb 13.

PMID:
16476674
17.

Levodopa enhances synaptic plasticity in the substantia nigra pars reticulata of Parkinson's disease patients.

Prescott IA, Dostrovsky JO, Moro E, Hodaie M, Lozano AM, Hutchison WD.

Brain. 2009 Feb;132(Pt 2):309-18. doi: 10.1093/brain/awn322. Epub 2008 Dec 2.

PMID:
19050033
18.

Relationship between levodopa concentration, dyskinesias, and motor effect in parkinsonian patients: a 3-year follow-up study.

Contin M, Riva R, Martinelli P, Albani F, Baruzzi A.

Clin Neuropharmacol. 1997 Oct;20(5):409-18.

PMID:
9331517
19.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
20.

[Current preclinical findings on substances against Parkinson's disease].

Gerlach M, Riederer P.

Nervenarzt. 2003 Mar;74 Suppl 1:S2-6. German.

PMID:
12624677

Supplemental Content

Support Center